Myriad Genetics Inc
XBER:MYD
Myriad Genetics Inc
XBER:MYD
Price:
5.3
EUR
Market Closed
Market Cap:
€476.5m
Relative Value
The Relative Value of one
MYD
stock under the Base Case scenario is
31.33
EUR.
Compared to the current market price of 5.3 EUR,
Myriad Genetics Inc
is
Undervalued by 83%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MYD
Relative Value
Base Case
31.33
EUR
Undervaluation 83%
Multiples Across Competitors
MYD Competitors Multiples
Myriad Genetics Inc Competitors
Myriad Genetics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Myriad Genetics Inc
XBER:MYD
|
428.2m EUR | 0.5 | -1.2 | -28.4 | -5.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.2 | 12.6 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 33.9 | 11.2 | 14.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 11.1 | 131.9 | 73.8 | 82 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
